Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,4396 USD | -0,54% | +2,23% | -40,60% |
Omzet 2023 * | - | Omzet 2024 * | - | Marktkapitalisatie | 1,65 mln. 1,54 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 * | -12 mln. -11,22 mln. | Nettowinst (verlies) 2024 * | - | EV/omzet 2023 * | - |
Nettoliquiditeiten 2023 * | - 0 | Nettoliquiditeiten 2024 * | - 0 | EV/omzet 2024 * | - |
K/w-verhouding 2023 * |
-0,06
x | K/w-verhouding 2024 * |
-
| Werknemers | 37 |
Dividendrendement 2023 * |
-
| Dividendrendement 2024 * |
-
| Vrij verhandelbaar | 86,62% |
Recentste transcriptie over NeuBase Therapeutics, Inc.
1 dag | -0,54% | ||
1 week | +2,23% | ||
Lopende maand | -2,29% | ||
1 maand | -8,19% | ||
3 maanden | -30,28% | ||
6 maanden | -30,64% | ||
Lopend jaar | -40,60% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Todd Branning
CEO | Chief Executive Officer | 54 | 10-01-22 |
Dani Stoltzfus
PRN | Corporate Officer/Principal | - | - |
Ron Sarkar
PRN | Corporate Officer/Principal | - | 01-11-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Dov Goldstein
CHM | Chairman | 56 | 12-07-19 |
Eric Richman
BRD | Director/Board Member | 63 | 12-07-19 |
Director/Board Member | 79 | 12-07-19 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 0,4396 | -0,54% | 72 170 |
25-04-24 | 0,442 | +4,99% | 25 641 |
24-04-24 | 0,421 | 0,00% | 21 218 |
23-04-24 | 0,421 | +0,24% | 58 425 |
22-04-24 | 0,42 | -2,33% | 157 792 |
uitgestelde koers Nasdaq, 26 april 2024 om 22:30 uur
Meer koersenVaira. 1 jan. | Kapi. | |
---|---|---|
-40,60% | 1,65 mln. | |
+1,51% | 42,75 mld. | |
+8,57% | 41,34 mld. | |
+49,22% | 41,61 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |